USSTOCK.TODAY
Market Closed
Log in Sign up

Acurx Pharmaceuticals begins patient enrollment for recurrent C. difficile clinical trial

The Motley Fool +1 · ·by G4L

ACXP
ACXP Acurx Pharmaceuticals Inc
$0.99 -4.37%
View chart & analysis →
  1. 1Acurx Pharmaceuticals has started patient enrollment for the PATHFINDER clinical trial involving 20 participants on September 29, 2026.
  2. 2Acurx Pharmaceuticals recorded a net loss of $2.6 million for the three months ended September 30, 2026.
  3. 3Acurx Pharmaceuticals' research and development expenses were $1.1 million for the three months ended September 30, 2026.

So what's the key point?

Acurx Pharmaceuticals has started a trial to check how effective a new medicine is in patients. The company recorded a loss of $2.6 million while spending on research costs.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Acurx Pharmaceuticals shares drop approximately 34% ahead of Q3 earnings release Earnings Whispers · 5d agoStratasys Q3 Revenue Up 4.1% and Annual Guidance Adjusted The Motley Fool +1 · 16m agoEli Lilly Announces GLP-1 Drug Efficacy and Raises Price Target The Motley Fool +1 · 16m ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news